Truffaux et al. (2015) compared dasatinib, an oral inhibitor of multiple targets (PDGFRA, PDGFRB, c-Kit, and SRC), monotherapy vs. combination therapy with cabozantinib, a potent inhibitor of c-Met, VEGFR2, and the proto-oncogene RET in a pre-clinical model of DIPG. Here, PDGFRB is linked to diffuse intrinsic pontine glioma.